Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
– 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control – – Tumor […]
